Adenosine A2A receptor agonists and PDE inhibitors: A synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

Blood

Volumn 116, Issue 4, 2010, Pages 593-602

  Rickles, Richard J ^a   Pierce, Laura T ^a   Giordano III, Thomas P ^a   Tam, Winnie F ^a   McMillin, Douglas W ^b   Delmore, Jake ^b   Laubach, Jacob P ^b   Borisy, Alexis A ^a   Richardson, Paul G ^b   Lee, Margaret S ^a  

^a Department of Preclinical Development and Formulations   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N 6 (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; CYCLIC AMP; DEXAMETHASONE; PAPAVERINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE VII; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; UPREGULATION; B LYMPHOCYTE; BLOOD DISEASE; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; EVALUATION; HIGH THROUGHPUT SCREENING; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GLUCOCORTICOIDS; HEMATOLOGIC NEOPLASMS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIPLE MYELOMA; PHOSPHODIESTERASE INHIBITORS; RECEPTOR, ADENOSINE A2A; VALIDATION STUDIES AS TOPIC;

EID: 77956050668     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-252668     Document Type: Article

References (27)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-2795.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
3. Smith ML, Newland AC. Treatment of myeloma. Q J Med. 1999;92(1):11-14.
4. Alexanian R, Haut A, Khan AU. Treatment for multiple myeloma. JAMA. 1969;208(9):1680-1685.
5. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
6. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. (Pubitemid 47477266)
7. Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood (ASH Annual Meeting Abstracts). 2008;112(11): Abstract 1742.
8. Mateos M-V, Hernandez J-M, Hernandez M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165-2172.
9. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4):1209-1217.
10. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
11. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A. 2003;100(13):7977-7982.
12. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;9(4):71-78.
13. Zimmermann GR, Avery W, Finelli AL, et al. Selective amplification of glucocorticoid antiinflammatory activity through synergistic multitarget action of a combination drug. Arthritis Res Ther. 2009;11(1):R12.
14. Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659-666.
15. Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11(suppl 1):S45-S55.
16. Greenstein S, Krett NL, Kurosawa, Y. et al. Characterization of the MM. 1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31(4):271-282. (Pubitemid 36407603)
17. Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103(8):3138-3147.
18. Chen YH, Desai P, Shiao RT, et al. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood. 1996;87(1):314-323. (Pubitemid 26011846)
19. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366-398.
20. Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247-264.
21. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488-520.
22. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2008;300(1-2):7-16.
23. Frankfurt O, Rosen ST. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol. 2004;16(6):553-563. (Pubitemid 39482974)
24. Ogawa R, Streiff MB, Bugayenko A, et al. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood. 2002;99(9):3390-3397.
25. Tiwari S, Dong H, Kim EJ, et al. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol. 2005;69(3):473-483.
26. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
27. Smith PG, Wang F, Wilkinson KM, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005;105(1):308-316.